INTERMOUNTAIN MEDICAL CENTER A new laboratory-based method of estimating outcomes for patients with a severe pulmonary disorder that has no cure can help physicians better provide proper care, referrals, and services for patients at the end of life, according to a new study of more than 17,000 patients from Intermountain Healthcare. The Laboratory-based Intermountain Validated Exacerbation (LIVE) score is a prediction model that predicts all-cause mortality, morbidity, and hospitalization rates for patients with chronic obstructive pulmonary disease (COPD),...
Tag: <span>Pulmonary</span>
Post
Telehealth pulmonary rehabilitation reduces 30-day readmissions
by Adam Pope, University of Alabama at Birmingham New research published in the American Journal of Respiratory and Critical Care Medicinefrom the University of Alabama at Birmingham shows that video telehealth pulmonary rehabilitation interventions reduce 30-day all-cause readmission rates following hospitalization for chronic obstructive pulmonary disease exacerbation. COPD includes a group of diseases, like emphysema and chronic bronchitis, that cause airflow obstruction and breathing-related problems....
Post
FDA: Pulmonary embolism risk up with tofacitinib 10 mg for RA
Currently, the 10-mg dose of tofacitinib is only approved in the dosing regimen for patients with ulcerative colitis. When tofacitinib received FDA approval, the agency called for a clinical trial among RA patients to evaluate the risk for heart-related events, cancer, and infections with tofacitinib doses of 5 mg and 10 mg twice daily combined...